The p.R183W mutation in PPP2R1A is associated with endometrial cancer development (Gonzalez-Bosquet et al. 2021) and confers increased resistance to clofarabine in uterine serous carcinoma cells through a gain-of-function mechanism (Remmerie et al. 2024). The gene discussed is PPP2R1A; the disease is endometrial serous adenocarcinoma.